Merck (MRK) says its TroFuse-005 trial evaluating sacituzumab tirumotecan met primary endpoints of overall survival and progression-free survival in certain patients with advanced or recurrent endometrial cancer

Merck's announcement regarding the successful results of its TroFuse-005 trial is a significant positive development for the company's oncology portfolio, potentially enhancing its positioning in the competitive landscape of cancer therapies.

Newsquawk StaffPublished 18 May 2026, 11:12 UTCOn the live feed at 10:52 UTC — 8 more headlines followed before this page went public

Newsquawk headlinesUTC

11:01

Rosatom head says the Zaporizhzhia nuclear power plant situation is rapidly approaching the point of no return, IFX reports

11:00

IMF upgrades the UK's 2026 GDP view to 1.0% (prev. 0.8%). Risks to growth are tilted to the downside.

10:52

Merck (MRK) says its TroFuse-005 trial evaluating sacituzumab tirumotecan met primary endpoints of overall survival and progression-free survival in certain patients with advanced or recurrent endometrial cancer

10:50

Compass Minerals (CMP) is considering a return to the lithium market and has signed an MOU with Energyx to extract lithium from Utah's Great Salt Lake, Reuters reports

10:48

EU reportedly plans tougher trade measures to rebuff China's export surge, Bloomberg reports

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free

Free. No signup, no card.

Context

Meeting the primary endpoints could bolster investor confidence and impact the stock positively, particularly given the increasing focus on advanced treatments within the pharmaceuticals sector. Observers will be keen to see how this news influences Merck's market performance and future guidance.

Equities · last 90 days

Recent headlines that moved markets

EQUITIES/8 Sept · 05:24 UTC

Saudi Energy Minister says a number of energy facilities and utilities were hit; are temporarily halting some operations.

Equity indices, after we published−0.3%

Modest downside seen across equity futures as energy prices tick higher.

EQUITIES/3 Sept · 04:54 UTC

North Korea stripped references to "peaceful unification" with South Korea from the charter of its ruling Workers' Party of Korea, according to Yonhap.

Equity indices, after we published−3.3%

EQUITIES/1 Sept · 16:17 UTC

Initial reports of an American attack on Iran, reports i24's Stein.

ES, after we published−0.2%

EQUITIES/26 Aug · 12:56 UTC

States and Meta (META) and agree to settle claims that platforms harmed children, according to a court filing; Meta agrees to pay a maximum of USD 16.68bln to states as part of deal

Market, after we published+2.6%

EQUITIES/8 Sept · 11:48 UTC

AstraZeneca (AZN LN) says Phase III tozorakimab data in COPD showed a 29%-34% reduction in exacerbations.

Market, after we published+1.0%

EQUITIES/7 Sept · 10:54 UTC

Saudi Aramco Jizan oil facilities were reportedly hit in new strikes, the FT reports citing sources; hit on Monday, damage is being assessed.

Equity indices, after we published−0.1%

Newsquawk Daily

Get both market opens in your inbox.

This note and the other one — the EU open and the US open, every business day, written by the desk. No account needed.

Related headlines

The whole workspace, free to try.

© 2026 Newsquawk. All rights reserved.